Simulations Plus (NASDAQ:SLP) Trading Down 8% – Should You Sell?

Shares of Simulations Plus, Inc. (NASDAQ:SLP) traded down 8% during trading on Thursday . The company traded as low as $33.22 and last traded at $33.02. 108,838 shares were traded during mid-day trading, a decline of 58% from the average session volume of 258,353 shares. The stock had previously closed at $35.90.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on SLP. BTIG Research cut their price target on shares of Simulations Plus from $60.00 to $50.00 and set a “buy” rating on the stock in a research note on Thursday, October 24th. StockNews.com lowered Simulations Plus from a “hold” rating to a “sell” rating in a research note on Monday, November 4th. KeyCorp lifted their price target on Simulations Plus from $35.00 to $37.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Stephens started coverage on Simulations Plus in a report on Friday, November 15th. They issued an “overweight” rating and a $39.00 price objective on the stock. Finally, William Blair reaffirmed an “outperform” rating on shares of Simulations Plus in a report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $49.40.

Simulations Plus Stock Performance

The firm has a market cap of $651.74 million, a PE ratio of 81.25 and a beta of 0.83. The stock has a 50 day simple moving average of $31.69 and a two-hundred day simple moving average of $32.19.

Insider Buying and Selling at Simulations Plus

In related news, Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $31.76, for a total value of $635,200.00. Following the sale, the director now owns 3,442,584 shares of the company’s stock, valued at approximately $109,336,467.84. This trade represents a 0.58 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 19.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Simulations Plus

Institutional investors and hedge funds have recently modified their holdings of the stock. First Horizon Advisors Inc. lifted its stake in shares of Simulations Plus by 82.6% in the third quarter. First Horizon Advisors Inc. now owns 818 shares of the technology company’s stock worth $26,000 after buying an additional 370 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Simulations Plus by 4.4% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,103 shares of the technology company’s stock worth $254,000 after buying an additional 380 shares during the last quarter. Jones Financial Companies Lllp grew its holdings in Simulations Plus by 53.6% in the 4th quarter. Jones Financial Companies Lllp now owns 1,223 shares of the technology company’s stock valued at $34,000 after buying an additional 427 shares in the last quarter. Pitcairn Co. increased its stake in shares of Simulations Plus by 9.1% in the 3rd quarter. Pitcairn Co. now owns 6,599 shares of the technology company’s stock worth $211,000 after acquiring an additional 549 shares during the last quarter. Finally, US Bancorp DE raised its holdings in shares of Simulations Plus by 14.3% during the 4th quarter. US Bancorp DE now owns 5,687 shares of the technology company’s stock worth $159,000 after acquiring an additional 713 shares during the period. Hedge funds and other institutional investors own 78.08% of the company’s stock.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.